Evidence map›Paper›PMID 28493228›Full record

SynthesisSchmerz (Berlin, Germany)2017

[Multimodal therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].

M Schiltenwolf, U Eidmann, V Köllner, T Kühn, M Offenbächer, F Petzke, M Sarholz, M Weigl, B Wolf, W Häuser

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Schmerz (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. [Fibromyalgia syndrome].Innere Medizin (Heidelberg, Germany) · 2026
    Review
  3. Patient Version of Guideline for Fibromyalgia (2025 Edition).Journal of evidence-based medicine · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

M SchiltenwolfSektion konservative Orthopädie, Zentrum für Orthopädie, Unfallchirurgie und Paraplegiologie, Universitätsklinikum Heidelberg, Schlierbacher Landstr. 200a, 69118, Heidelberg, Deutschland. marcus.schiltenwolf@med.uni-heidelberg.de.
U EidmannDeutsche Rheuma-Liga, Bonn, Deutschland.
V KöllnerAbteilung für Psychosomatische Medizin und Verhaltenstherapie, Rehazentrum Seehof der Deutschen Rentenversicherung, Teltow, Deutschland.
T KühnDeutsche Rheuma-Liga, Ellwangen, Deutschland.
M OffenbächerInstitut für Allgemeinmedizin, Klinikum der Universität München, Campus Innenstadt, München, Deutschland.
F PetzkeSchmerzmedizin, Klinik für Anästhesiologie, Universitätsmedizin Göttingen, Göttingen, Deutschland.
M SarholzRheumazentrum Ruhrgebiet, Herne, Deutschland.
M WeiglKlinik und Poliklinik für Orthopädie, Physikalische Medizin und Rehabilitation, Klinikum der Universität München, München, Deutschland.
B WolfDeutsche Fibromyalgie Vereinigung, Seckach, Deutschland.
W HäuserInnere Medizin I, Klinikum Saarbrücken gGmbH, Saarbrücken, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe regular update of the guidelines on fibromyalgia syndrome, AWMF number 145/004, was scheduled for April 2017.

methodsThe guidelines were developed by 13 scientific societies and 2 patient self-help organizations coordinated by the German Pain Society. Working groups (n = 8) with a total of 42 members were formed balanced with respect to gender, medical expertise, position in the medical or scientific hierarchy and potential conflicts of interest. A search of the literature for systematic reviews on randomized controlled trials of multimodal therapy from December 2010 to May 2016 was performed in the Cochrane library, MEDLINE, PsycINFO and Scopus databases. Levels of evidence were assigned according to the classification system of the Oxford Centre for Evidence-Based Medicine version 2009. The strength of recommendations was achieved by multiple step formalized procedures to reach a consensus. Efficacy, risks, patient preferences and applicability of available therapies were weighed up against each other. The guidelines were reviewed and approved by the board of directors of the societies engaged in the development of the guidelines. RESULTS AND

conclusionThe use of multimodal therapy (combination of aerobic exercise with at least one psychological therapy) with a duration of at least 24 h is strongly recommended for patients with severe forms of fibromyalgia.

Indexed as

Practice Guidelines as TopicCombined Modality TherapyEvidence-Based MedicineExerciseFibromyalgiaGermanyHumansPsychotherapyRandomized Controlled Trials as TopicSocieties, MedicalFibromyalgia syndromeGuidelinesMedicine, evidence-basedMulticomponent therapyReview, systematic

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.